Loading…
← CockpitCompetitor Analysis › 688075.SS Assure Tech (Hangzhou) Co. Ltd. Class AOpen in the cockpit ↗

Assure Tech (Hangzhou) Co. Ltd. Class A688075.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum neutral 57
Mkt cap
$508M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$1.99M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-8.2 pp
WACC 8.7%
Hurdle
+49 pp
Req g minus delivered
Close · CNYCN¥26.64
1D-1.5%
1W-5.9%
1M-9.6%
3M-10.0%
6M-26.9%
YTD-31.1%
1Y-32.7%
ATR %2.9%
52w lowhigh40.8% off high

What Assure Tech (Hangzhou) does

Employees: 551

Assure Tech (Hangzhou) at a glance

Size Assure Tech (Hangzhou) (688075.SS) is a China Health Care company (Medical Specialties) with a market value of $508M, the 3671st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.64 on 18 Nov 2026.

Performance Over six months the shares fell 26.9%, against -16.1% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 9.5% over the last twelve months (peer median +7.0%); the operating margin is -7.9% (peer median 3.5%).

Valuation It trades at 5.4× enterprise value to sales against a peer median of 2.4× (6th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is -19%, so the hurdle is +49 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.2 points below its cost of capital (8.7% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 85688075.SS 74
Six months, rebased to 100: Assure Tech (Hangzhou) against the median of its 20 peers (local-currency closes).

Assure Tech (Hangzhou) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥419MCN¥427MCN¥537MCN¥495MCN¥6.12B
Revenue growth—-20%+9%-92%—
Gross profitCN¥225MCN¥147MCN¥185MCN¥181MCN¥4.55B
EBITDAn/aCN¥19.5MCN¥38.3MCN¥52.9MCN¥3.23B
Net income-CN¥25.4MCN¥69.4MCN¥192MCN¥142MCN¥3.04B
Free cash flowCN¥144MCN¥26.8MCN¥111M-CN¥840MCN¥3.18B
Capital expenditureCN¥77.4MCN¥95.6MCN¥107MCN¥337MCN¥627M
Total debtCN¥189MCN¥94.5MCN¥82.0MCN¥118MCN¥212M

Quarterly statements and history in the cockpit →

Assure Tech (Hangzhou) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%AVR7979300639688298688580NNNN300439MEDX603520RCELMYGN002932ZJYL688606300246CEVIANGO603309688075.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Assure Tech (Hangzhou) is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%0×50×100×AVR7979300639688298688580300439MEDXRCELMYGNZJYL688606301033CEVI688075.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Assure Tech (Hangzhou) is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%300639688580300439MEDX688606301033300246CEVI605369603309688075.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Assure Tech (Hangzhou) is the large dot.

Assure Tech (Hangzhou) competitors and peer comparison

How Assure Tech (Hangzhou) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Assure Tech (Hangzhou) against its 20 peers (data as of 18 Nov 2026)
Measure688075.SSPeer medianRank in peer set
1-month return-9.6%-3.8%4th lowest of 21
6-month return-26.9%-16.1%7th lowest of 21
Distance from 52-week high-40.8%-37.7%11th highest of 21
Revenue growth (TTM)-9.5%+7.0%2nd lowest of 21
Operating margin-7.9%3.5%6th lowest of 21
EV / Sales5.4×2.4×6th most expensive of 19
Growth the price implies (Req g, 7 yrs)30.8%5.3%2nd most demanding of 11
Growth delivered (Del g)-18.6%+4.6%lowest of 11
Hurdle (Req g minus delivered)+49.4 pp+1.6 pp2nd most demanding of 11
ROIC minus cost of capital-8.2 pp-1.3 pp6th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%5.4×30.8%-18.6%
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%125.0×n/an/a
Shofu 7979.TJapan$510M+32%+9%14%1.6×n/an/a
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%3.9×0.4%-13.2%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%1.6×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%1.5×6.0%-7.7%
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%7.0×4.3%+24.4%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%3.1×55.3%-4.7%
CellaVision CEVI.STSweden$477M+64%+2%23%6.1×7.1%+10.0%
AngioDynamics ANGOUnited States$476M-4%+8%-6%1.4×n/an/a
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%2.0×-5.9%+7.7%

Questions

Which companies are Assure Tech (Hangzhou)'s closest peers?
The cockpit's peer set: Anteris Technologies Global (AVR), Shofu (7979.T), Guangdong Hybribio Biotech (300639.SZ), Zhejiang Orient Gene Biotech (688298.SS), Nanjing Vishee Medical Technology (688580.SS), Anbio Biotechnology (NNNN), MedicalSystem Biotechnology (300439.SZ), medmix (MEDX.SW).
Is Assure Tech (Hangzhou) expensive compared with its peers?
On ev / sales it trades at 5.4× against a peer median of 2.4×, 6th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is -19%, so the hurdle is +49 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Assure Tech (Hangzhou) stock performed?
Over six months to 18 Nov 2026 the shares returned -26.9% against -16.1% for the median peer; over one year -32.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.